Effect of docetaxel, estramustine and carboplatin chemotherapy on castration-resistant prostate cancer

Effect of docetaxel, estramustine and carboplatin chemotherapy on castration-resistant prostate cancer - DEC

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027129

Enrollment

100

Registered

2017-05-01

Start date

2013-06-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CRPC

Interventions

Chemotherapy

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1 Male 2 Older tha 18 3 Patients agree with this study

Exclusion criteria

Exclusion criteria: 1 Patients who can not visit our hospitall 2 History of allergy on DEC agents 3 Patiens whom the doctor don't think appropriate

Design outcomes

Primary

Measure	Time frame
survival, QOL	—

Countries

Japan

Contacts

Public ContactMasahiro Sumura

Shimane University Urology

sumura@med.shimane-u.ac.jp0853202256

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026